|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||45.13 - 46.66|
|52-week range||43.25 - 89.70|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||22.58|
|Earnings date||09 Feb 2023|
|Forward dividend & yield||1.16 (2.54%)|
|Ex-dividend date||01 Dec 2022|
|1y target est||58.94|
Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Combines Miromatrix’s expertise in bioengineered organs with Baxter’s leadership in critical care delivery and organ support therapiesIncludes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering from acute liver failure EDEN PRAIRIE, Minn. and DEERFIELD, Ill., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agree